Emergent Biosolutions

Emergent Biosolutions wins $4.9 million anthrax vaccine grant from the National Institute of Allergy and Infectious Diseases. The grant is for dmPA7909, which was designed to meet the US need for an advanced anthrax vaccine that can provide a rapid immune response with long term stability.

Emergent Biosolutions wins $4.9 million anthrax vaccine grant from the National Institute of Allergy and Infectious Diseases. The grant is for dmPA7909, which was designed to meet the US need for an advanced anthrax vaccine that can provide a rapid immune response with long term stability.

Not such good news for prospective anthrax vaccine manufacturer Human Genome Science, however, they were questioned by the FDA as to whether it worked better than existing treatments. They have questioned the efficacy in humans because of the large amount of animal testing done – human testing was only done on safety, rather than efficacy against anthrax. Their ABthrax has not yet received regulatory approval, but this has not stopped DHS purchasing 20,000 doses for Emergency Use in the national stockpile.
--------------------------------------------------------------------------------

Tags: Emergency

Our Current Sponsors

  • Flir
  • BioFire Defense
  • Federal Resources
  • Cristanini
  • Airboss
  • Flir
  • Argon
  • 908 Devices
  • Avon
  • Battelle
  • Flir
  • Bw Tek
  • CQC
  • Decon Seven Systems
  • DQE
  • Flir
  • Dxterity
  • First Line Technology
  • Futurtech
  • Metrohm Raman
  • Flir
  • NBC sys
  • Proengin
  • Qinetiq
  • Tex Shield
  • Flir
  • Wl Gore
  • ADS, Inc.
  • Rigaku Analytical Devices
  • Paul Boye Technologies
  • Flir
  • Observis
  • Zeteo Tech
  • Bertin Instruments
  • ECOTEST